dpp hiv 1 2 igm Search Results


dpp hiv 1 2 igm  (HyTest)
94
HyTest dpp hiv 1 2 igm
Antibody detection in <t>HIV-1</t> seroconversion panel PRB-927 and effect of sample pretreatment with 0.1 M 2-ME. (A) Micro Reader reflectance values generated with the <t>DPP</t> HIV 1/2 (red lines) and DPP HIV 1/2 IgM assays (blue lines) are shown for samples tested before (solid lines) and after 2-ME treatment (dashed lines). Framed are test results for samples 03 and 04 collected during initial IgM seroconversion (days 33 and 35 since 1st bleed), in which antibody detection by each of the two immunoassays was diminished after 2-ME treatment by at least 50% signal reduction. (B) Results show differentially evolving susceptibility to the 2-ME treatment of postseroconversion samples tested by the DPP HIV 1/2 (red line) and DPP HIV 1/2 IgM assays (blue line). Framed is the same data subset as that included in panel A but results are shown in percent signal reduction over time.
Dpp Hiv 1 2 Igm, supplied by HyTest, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dpp+hiv+1+2+igm/pmc09769532-145-14-37?v=HyTest
Average 94 stars, based on 1 article reviews
dpp hiv 1 2 igm - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier

Image Search Results


Antibody detection in HIV-1 seroconversion panel PRB-927 and effect of sample pretreatment with 0.1 M 2-ME. (A) Micro Reader reflectance values generated with the DPP HIV 1/2 (red lines) and DPP HIV 1/2 IgM assays (blue lines) are shown for samples tested before (solid lines) and after 2-ME treatment (dashed lines). Framed are test results for samples 03 and 04 collected during initial IgM seroconversion (days 33 and 35 since 1st bleed), in which antibody detection by each of the two immunoassays was diminished after 2-ME treatment by at least 50% signal reduction. (B) Results show differentially evolving susceptibility to the 2-ME treatment of postseroconversion samples tested by the DPP HIV 1/2 (red line) and DPP HIV 1/2 IgM assays (blue line). Framed is the same data subset as that included in panel A but results are shown in percent signal reduction over time.

Journal: Microbiology Spectrum

Article Title: Rapid Point-of-Care Tests Using Staphylococcal Protein A Can Detect Early IgM Responses in HIV-1 and Treponema pallidum Infections

doi: 10.1128/spectrum.03309-22

Figure Lengend Snippet: Antibody detection in HIV-1 seroconversion panel PRB-927 and effect of sample pretreatment with 0.1 M 2-ME. (A) Micro Reader reflectance values generated with the DPP HIV 1/2 (red lines) and DPP HIV 1/2 IgM assays (blue lines) are shown for samples tested before (solid lines) and after 2-ME treatment (dashed lines). Framed are test results for samples 03 and 04 collected during initial IgM seroconversion (days 33 and 35 since 1st bleed), in which antibody detection by each of the two immunoassays was diminished after 2-ME treatment by at least 50% signal reduction. (B) Results show differentially evolving susceptibility to the 2-ME treatment of postseroconversion samples tested by the DPP HIV 1/2 (red line) and DPP HIV 1/2 IgM assays (blue line). Framed is the same data subset as that included in panel A but results are shown in percent signal reduction over time.

Article Snippet: DPP HIV 1/2 and DPP HIV-Syphilis tests were converted into investigational IgM-detecting assays, named DPP HIV 1/2 IgM and DPP HIV-Syphilis IgM, respectively, by replacing SpA coupled to gold nanoparticles with mouse monoclonal antibody to human IgM (HyTest Ltd., Turku, Finland), a specific reagent for IgM detection validated in commercial DPP products ( , ).

Techniques: Generated

IgM antibody detection by SpA-based rapid point-of-care tests in HIV-1 seroconversion panels <xref ref-type= a " width="100%" height="100%">

Journal: Microbiology Spectrum

Article Title: Rapid Point-of-Care Tests Using Staphylococcal Protein A Can Detect Early IgM Responses in HIV-1 and Treponema pallidum Infections

doi: 10.1128/spectrum.03309-22

Figure Lengend Snippet: IgM antibody detection by SpA-based rapid point-of-care tests in HIV-1 seroconversion panels a

Article Snippet: DPP HIV 1/2 and DPP HIV-Syphilis tests were converted into investigational IgM-detecting assays, named DPP HIV 1/2 IgM and DPP HIV-Syphilis IgM, respectively, by replacing SpA coupled to gold nanoparticles with mouse monoclonal antibody to human IgM (HyTest Ltd., Turku, Finland), a specific reagent for IgM detection validated in commercial DPP products ( , ).

Techniques:

Antibody detection in AccuVert Syphilis Seroconversion Panel PSS901 and effect of sample pre-treatment with 0.1 M 2-ME. (A) Micro Reader reflectance values generated with the DPP HIV-Syphilis (red lines) and DPP HIV-Syphilis IgM assays (blue lines) are shown for samples tested before (solid lines) and after 2-ME treatment (dashed lines). Framed are test results for samples 06 to 09 collected during the initial IgM response (days 45 to 59 since 1st bleed), in which antibody detection with each of the two immunoassays was diminished after 2-ME treatment by at least 50% signal reduction. (B) Results show differentially evolving susceptibility to the 2-ME treatment of postseroconversion samples (same as framed in panel A) tested by the DPP HIV-Syphilis (red line) and DPP HIV-Syphilis IgM assays (blue line).

Journal: Microbiology Spectrum

Article Title: Rapid Point-of-Care Tests Using Staphylococcal Protein A Can Detect Early IgM Responses in HIV-1 and Treponema pallidum Infections

doi: 10.1128/spectrum.03309-22

Figure Lengend Snippet: Antibody detection in AccuVert Syphilis Seroconversion Panel PSS901 and effect of sample pre-treatment with 0.1 M 2-ME. (A) Micro Reader reflectance values generated with the DPP HIV-Syphilis (red lines) and DPP HIV-Syphilis IgM assays (blue lines) are shown for samples tested before (solid lines) and after 2-ME treatment (dashed lines). Framed are test results for samples 06 to 09 collected during the initial IgM response (days 45 to 59 since 1st bleed), in which antibody detection with each of the two immunoassays was diminished after 2-ME treatment by at least 50% signal reduction. (B) Results show differentially evolving susceptibility to the 2-ME treatment of postseroconversion samples (same as framed in panel A) tested by the DPP HIV-Syphilis (red line) and DPP HIV-Syphilis IgM assays (blue line).

Article Snippet: DPP HIV 1/2 and DPP HIV-Syphilis tests were converted into investigational IgM-detecting assays, named DPP HIV 1/2 IgM and DPP HIV-Syphilis IgM, respectively, by replacing SpA coupled to gold nanoparticles with mouse monoclonal antibody to human IgM (HyTest Ltd., Turku, Finland), a specific reagent for IgM detection validated in commercial DPP products ( , ).

Techniques: Generated

IgM antibody detection by DPP HIV-Syphilis assay in active syphilis <xref ref-type= a " width="100%" height="100%">

Journal: Microbiology Spectrum

Article Title: Rapid Point-of-Care Tests Using Staphylococcal Protein A Can Detect Early IgM Responses in HIV-1 and Treponema pallidum Infections

doi: 10.1128/spectrum.03309-22

Figure Lengend Snippet: IgM antibody detection by DPP HIV-Syphilis assay in active syphilis a

Article Snippet: DPP HIV 1/2 and DPP HIV-Syphilis tests were converted into investigational IgM-detecting assays, named DPP HIV 1/2 IgM and DPP HIV-Syphilis IgM, respectively, by replacing SpA coupled to gold nanoparticles with mouse monoclonal antibody to human IgM (HyTest Ltd., Turku, Finland), a specific reagent for IgM detection validated in commercial DPP products ( , ).

Techniques:

Correlation between antibody levels detected by SpA or anti-IgM reagent in early HIV-1 seroconversion and syphilis samples. (A) Micro Reader reflectance values generated with the DPP HIV-1/2 and DPP HIV-1/2 IgM assays are shown for the HIV-1 seroconversion samples included in <xref ref-type=Table 1 , Groups 2 and 3 (circles), and matching preseroconversion members (triangles). (B) Micro Reader reflectance values generated for treponemal antibody levels with the DPP HIV-Syphilis and DPP HIV-Syphilis IgM assays are shown for the syphilis-positive samples listed in Table 2 (circles) and preseroconversion panel members (triangles). Horizontal and vertical dashed lines indicate cutoff values used for test interpretation: DPP HIV-1/2, 10 RLU; DPP HIV-1/2 IgM, 40 RLU; DPP HIV-Syphilis, 7 RLU; DPP HIV-Syphilis IgM, 60 RLU. " width="100%" height="100%">

Journal: Microbiology Spectrum

Article Title: Rapid Point-of-Care Tests Using Staphylococcal Protein A Can Detect Early IgM Responses in HIV-1 and Treponema pallidum Infections

doi: 10.1128/spectrum.03309-22

Figure Lengend Snippet: Correlation between antibody levels detected by SpA or anti-IgM reagent in early HIV-1 seroconversion and syphilis samples. (A) Micro Reader reflectance values generated with the DPP HIV-1/2 and DPP HIV-1/2 IgM assays are shown for the HIV-1 seroconversion samples included in Table 1 , Groups 2 and 3 (circles), and matching preseroconversion members (triangles). (B) Micro Reader reflectance values generated for treponemal antibody levels with the DPP HIV-Syphilis and DPP HIV-Syphilis IgM assays are shown for the syphilis-positive samples listed in Table 2 (circles) and preseroconversion panel members (triangles). Horizontal and vertical dashed lines indicate cutoff values used for test interpretation: DPP HIV-1/2, 10 RLU; DPP HIV-1/2 IgM, 40 RLU; DPP HIV-Syphilis, 7 RLU; DPP HIV-Syphilis IgM, 60 RLU.

Article Snippet: DPP HIV 1/2 and DPP HIV-Syphilis tests were converted into investigational IgM-detecting assays, named DPP HIV 1/2 IgM and DPP HIV-Syphilis IgM, respectively, by replacing SpA coupled to gold nanoparticles with mouse monoclonal antibody to human IgM (HyTest Ltd., Turku, Finland), a specific reagent for IgM detection validated in commercial DPP products ( , ).

Techniques: Generated